Article CommentaryExclusivement sur le web

Défis posés par les nouveaux traitements de la maladie d’Alzheimer

L’approbation accélérée de l’aducanumab aux États-Unis soulève des questions

David Hogan and Chris Frank
Canadian Family Physician March 2023, 69 (3) e49-e51; DOI: https://doi.org/10.46747/cfp.6903e49
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Respond to this article
Défis posés par les nouveaux traitements de la maladie d’Alzheimer
David Hogan, Chris Frank
Canadian Family Physician Mar 2023, 69 (3) e49-e51; DOI: 10.46747/cfp.6903e49
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Subjects